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Prehabilitation
“By failing to prepare, you are preparing to fail.” 
  Benjamin Franklin
Delivery of care for patients with oesophageal cancer is no longer the preserve of single modality surgical intervention but has become a multifactorial ‘aggregation of marginal gains’ in multidisciplinary practice. This review aims to explore the benefits of exercise prehabilitation in oesophageal cancer treatment.
Background
The physiological impact of having an oesophagectomy is often likened to that of running a marathon. Whilst nobody would consider starting a marathon without months of dedicated preparation, the majority of patients scheduled for surgery undergo little or no physical training in the lead up to their operation. 
In recent years, Enhanced Recovery After Surgery Programs (ERAS/ERP) have resulted in improved short-term outcomes after surgery (1) and have widely been integrated into surgical-oncology pathways as best practice. Yet, increasing the expectations on patients recovering from high-risk surgery without preparing them physically makes little sense. In some disciplines, where pre-operative exercise programs have been introduced to optimise physical function in patients before surgery, a positive benefit on post-operative functional capacity and return to activities of daily living has been seen in the short-term(2). Physical or 
Keywords:Oesophageal cancer SurgeryPrehabilitationEnhanced Recovery after Surgery
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multimodal prehabilitation of patients before cardiovascular, abdominal and colorectal cancer surgery has resulted in improved pre-and post-operative functional capacity (3–5). However, the focus in these programs has been in the peri-operative period. The opportunity for extended prehabilitation from the time of diagnosis, through neo-adjuvant oncological therapy, is the subject of a number of on-going clinical trials. (Table 1) 
Current status in oesophago-gastric cancer
In patients diagnosed with locally advanced oesophago-gastric cancers, neo-adjuvant chemotherapy (NAC) or chemo-radiotherapy (NACRT) followed by surgery remains the treatment of choice (6,7). Introduction of neo-adjuvant oncological therapies has resulted in improved overall and disease-free survival (8,9). However, the effects of neo-adjuvant chemotherapy result in physiological deconditioning. In a study using cardiopulmonary exercise (CPEX) testing before and after NAC, Jack et al recorded a 15% decline in oxygen uptake at estimated lactate threshold in patients due to undergo oesophago-gastric surgery (10).
Improvements in surgical techniques, including minimally invasive and robotic surgery, and centralisation of surgery to specialist centres have improved safety. As a result, the 30 day post-operative mortality has reduced from 10.3% to 1.9%  in the UK national audit (11,12). ERAS programs have resulted in reduced length of stay and readmissions to hospital after surgery(1). However, whilst mortality rates have fallen, reported post-operative morbidity rates of 36 – 59% (13–15) and resolution of quality of life remain a significant challenge - both of which may conceivably be improved by prehabilitation.
The demographic of patients being diagnosed with potentially ‘curable’ oesophageal cancer is also a changing landscape. With the ageing population, older patients on poly-pharmacy regimens are presenting with tumours that are 
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technically surgically resectable but who are of borderline fitness for high-risk and physiologically demanding surgery. Profoundly unfit patients with comorbidities relating to sedentary lifestyles are also being seen with a cancer diagnosis at a young age.
The health benefits of exercise are well established (16).  These include lower mortality and morbidity rates (17,18), improved cardiovascular function, strength and muscle mass, postural stability and psychological function, improvements in depressive symptoms and sleep disorders(19) and better overall quality of life (20). With the safety and benefits of exercise during cancer treatment being accepted as a principle(21,22) and encouraged by cancer support organisations (23), the focus of attention in oesophageal cancer has turned to prehabilitation before surgery, specifically encompassing the neo-adjuvant treatment period. 
Heldens et al. (24) reported on the feasibility of a structured exercise program during neo-adjuvant chemo-radiotherapy in patients diagnosed with rectal cancer. They concluded that an outpatient prehabilitation program was largely feasible and safe, and not only prevented the reduction in physical fitness decline associated with NACRT but improved functional exercise capacity by 9.0% and leg muscle strength by 39.2%.
Pre-operative programs, focusing mainly on respiratory function, have shown mixed results across a variety of surgical disciplines, including cancer(25). Dettling et al. reported on the benefits of Inspiratory Muscle Training (IMT) as significantly improving respiratory muscle function but with no benefit on post-operative pneumonia following oesophagectomy (26).  However Boden et al. reported a 50% reduction in postoperative pulmonary complications after major upper abdominal surgery following a single preoperative physiotherapy session (27). An increase in inspiratory muscle function but no increase in peripheral muscle strength or aerobic capacity using IMT, was reported by Valkenet at al. 
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who suggested that the limited benefits were partly due to a short interval between screening and surgery.(28)
In a trial, which included pre-operative aerobic and resistance training versus rehabilitation in colorectal cancer patients, Gillis et al. reported similar hospital length of stay and post-operative outcomes (29). However, there was an improvement in 6-min walk test (6MWT) in the prehabilitation group at 8 weeks after surgery when compared to the rehabilitation group, suggesting a better maintained physical capacity and/or accelerated recovery post-surgery following prehabilitation.
Prehabilitation in surgery
Tew et al.(30), in their ‘Clinical guidelines and recommendations on pre-operative exercise training in patients awaiting major non-cardiac surgery’, graphically represent the physical trajectory of prehabilitation before surgery with the anticipated post-surgery improvement in functional capacity, versus that of the non-optimised surgical patient (Figure 1).
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Figure 1 The prehabilitation concept. Following major surgical intervention all patients experience and acute drop in physiological reserve/functional capacity followed by a recovery and rehabilitation phase (A). A low physiological reserve/functional capacity may increase the risk of peri-operative complications and lead to slower, sometimes incomplete recovery (B). A prehabilitated patient may possess greater physiological reserve/functional capacity at the time of surgery, facilitating a more rapid and complete recovery (C). Crucially, in the event of a complicated recovery, prehabilitated patients may be better placed to retain their functional independence and quality of life in the longer term (D).(30) Printed with permission Copyright © 2018 The Association of Anaesthetists of Great Britain and Ireland 
A summary of their key recommendations on peri-operative exercise include: 
 Priority of patient selection, especially those identified with a higher risk of 
peri-operative complications  
 Multimodal interventions including: smoking cessation; reduction in alcohol 
intake; and treatment of anaemia
 Presentation of the exercise program as pre-operative optimisation rather than 
as an optional extra
 Initial patient assessment, including comorbidity optimisation, risk evaluation 
and education on the benefits of exercise
 Objective functional evaluation and quality of life assessment
 Ongoing ‘response to training’ functional assessments
 Sufficient time for intervention, commencing as early in the surgical pathway 
as possible, ideally with a minimum of 4 weeks before surgery
 A combination of aerobic training, resistance training and inspiratory muscle 
training, tailored to each patient
 Supervised programs by trained individuals. Self-managed programs may be 
suitable in selected individuals.
In an elective surgical patient group, these are valuable and important recommendations. However, there are challenges in following these guidelines within a cancer treatment pathway. Patient selection after a diagnosis of cancer is based largely on tumour-stage and patient fitness. With ‘time-to-treat’ targets and established cancer treatment pathway guidelines, there is little time for optimization of modifiable comorbidities and lifestyle factors particularly if these interventions are constrained to the narrow window between diagnosis and start of NAC. Patient fitness, in the majority of these patients, is already compromised. Cramer et al. found that, on average, colorectal cancer patients had a baseline VO2 peak of 23% below that of general population, age-matched controls (31). To compound this, patients frequently develop induced complication toxicities from 
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chemotherapeutic agents. Anthracyclines and anti-angiogenic targeted therapies, commonly used in the neo-adjuvant pathway, lead to increased exercise intolerance in cancer patients (32).  In the UK MRC OE05 chemotherapy trial, 12% of patients stopped chemotherapy early due to toxicities and 11 % of patients did not proceed to surgery. Of these, 15% developed significant comorbidities that precluded surgery. The mortality from combined Epirubicin, Cisplatin and Capecitabine (ECX) chemotherapy was 1.8%, equivalent to the post-operative mortality seen in the trial (33).  
Therefore, a diagnosis of cancer, and especially oesophageal cancer, results in a unique group of patients requiring an individualised or tailored approach to prehabilitation. This mandates a fundamental understanding of the treatments they receive and an appreciation that the exercise intervention may differ at the various stages of the treatment pathway.  
Prehabilitation in cancer
Silver and Baima describe cancer prehabilitation as “a process on the cancer 
continuum of care that occurs between the time of cancer diagnosis and the 
beginning of acute treatment, includes physical and psychological assessments that 
establish a baseline function level, identifies impairments, and provides targeted 
interventions that improve a patient’s health to reduce the incidence and the severity 
of current and future impairments” (34).
Table 1 represents the current landscape of registered clinical trials of pre-operative exercise interventions in oesophageal cancer, focusing on those during NAC. They are limited to relatively small, prospective studies with numerous primary end-points and large variations in how physical function is measured.Each study has been evaluated according to Silver’s definition of prehabilitation in cancer (34). The few studies that have reported results mainly include exercise 
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interventions focusing on pre-operative respiratory muscle training with the aim of reducing post-operative pulmonary complications.  The awaited results will help to inform and shape the future of UGI cancer prehabilitation. 
A number of important points are highlighted from the Silver’s description that present challenges that need to be met in any attempt to successfully deliver prehabilitation in cancer patients:
1. A process on the cancer continuum of careA continuum is ‘A continuous sequence in which adjacent elements are not 
perceptibly different from each other, but the extremes are quite distinct.’ (35)
In the context of the cancer patient, the investigative and treatment pathways may feel like a continuum. However, in reality, there are distinct needs during each element from diagnosis, through chemotherapy, surgery and into the recovery period. 
The exercise advice given to a treatment-naïve patient will differ from that of a patient during active chemotherapy treatment especially in the first days following chemotherapy infusions. In the ‘washout period’ after NAC, as the effects of chemotherapy toxicities subside, activity may be designed to increase in intensity in preparation for surgery. Nutritional and psychological support, will likewise adjust to each phase of treatment. In-hospital physiotherapy teams will oversee early post-operative recovery, but following discharge, any exercise program clearly needs to be sympathetic to the resultant physical deficiencies incurred by the surgery. 
ACCEPTED MANUSCRIPT
9
2. Between the time of diagnosis and the beginning of acute treatmentThe timing of introducing prehabilitation programs poses a significant challenge with regards to imposed ‘time-to-treat’ treatment pathways. Once staging has been completed, patients may be required to attend the hospital multiple times for additional investigations including renal and cardiac function, and nutritional optimization prior to starting neo-adjuvant chemotherapy. Patients also take time to process the diagnosis of cancer and the impact it will have on their lives and that of their families (36). Initiating exercise training during this period is challenging. Opportunities for exercise training need to be accessible and preferably provided on-site to avoid additional travel for patients (37).
Prehabilitation during NAC aims to reduce physical deconditioning, increase pre-operative activity levels and as a result, optimise fitness and improved mental and emotional health ahead of demanding surgery. Much of the reported research in exercise training has focused on the 2 – 6 weeks before surgery. In Figure 2, Jack et al. present the CPEX results of VO2peak before and after NAC showing decline of physical function in patients during treatment (10). This study highlights that exercise interventions, in patients undergoing neo-adjuvant treatments, need to be introduced from the time of diagnosis rather than waiting to begin prehabilitation in the pre-surgery period. 
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Figure 2 A ladder plot of oxygen uptake at estimated lactate threshold pre-and-post-neoadjuvant chemotherapy (NAC) (10)    Printed with permission Copyright © 2014 Elsevier Ltd. All rights reserved
3. Physical and psychological assessments that establish a baseline function 
levelThere is general consensus (30,38) that patients undergoing prehabilitation in cancer should undergo baseline assessment of physical and psychological function. Cancer treatment is physically, emotionally and psychologically stressful(39,40) . Each patient will have unique comorbidities and physical capabilities. As a result, physical training needs to be individualized to those specific needs, measured against a baseline assessment and with subsequent monitoring and guidance during training (30) .
In clinical trials, baseline assessments vary and may include: 6-minute walk test, muscle function/strength tests (i.e. leg press and chest press), VO2max as measured by Cardiopulmonary Exercise Test (CPEX) or estimated from a sub-maximal test, grip strength, Forced Expiratory Volumes (FEV), in addition to measures of insulin resistance, haemoglobin, white cell and blood albumin levels. 
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Cardiopulmonary exercise testing (CPEX) is a holistic measure of cardiorespiratory capacity and oxygen delivery within an individual, including that of skeletal muscle function(41). It is a useful tool in risk stratifying patients, may predict post-operative morbidity and can guide exercise prehabilitation programs (42). Early mobilization of patients is a key aspect of ERAS programs for good reason, given that the pulmonary and systemic circulation, and peripheral muscle function are all activated through ambulation of patients post-operatively. Some of the ‘softer’ physical measures, for example, 6MWT, grip strength and Forced Expiration Volume (FEV) used in studies are restricted in how they measure overall physical function. However these limitations need to be weighed against advantages such as ease of access, cost and time taken to perform the test. 
Validated psychological and well-being measures are readily available for use in cancer patients (43–45). Baseline measures will serve to inform the clinical team of a patient’s current status, may highlight important areas where intervention may be required and also provide valuable context during the survivorship period.
4. Identifies impairmentsWhilst surgery is still considered to be the cornerstone of curative treatment, discussion with the patient involves identifying limiting factors prior to treatment selection. Pre-existing comorbidities and specific cancer-related risk factors need to be considered in relation to the toxicities resulting from chemotherapy and chemo-radiation treatments. Renal, cardiac and pulmonary function, in addition to smoking status, synchronous cancers, morbid obesity and mental health are all considerable risk factors for patients. The need for single lung ventilation during oesophagectomy needs to be considered at the outset in relation to patient fitness for surgery.
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The Eastern Cooperative Oncology Group (ECOG) Performance Status (46) is a standard used by oncologists to establish how the patient’s disease affects their daily living abilities and to determine appropriate treatment. Furthermore, personal goals and patient wishes should be considered. An understanding of the benefits of physical exercise will have a significant influence on the patient’s compliance when enrolling in exercise programs. The concept of “teachable moments” where patients are receptive to, and may act upon, health advice is particularly relevant to prehabilitation. Nadler et al. discuss some of the barriers relating to exercise during cancer treatment including, poor knowledge, lack of time and safety concerns (47). Advice from oncology care providers may be important in addressing these concerns. In addition, tailored exercise programs, targeted to the needs and preferences of the patient, combined with the use of group activities including family and friends, and regular monitoring with feedback, are some of a number of ways to improve motivation and adherence.
 A number of strategies are emerging to adequately assess elderly and more complex patients prior to surgery. These include dedicated, high-risk, anaesthetic clinics and specific services overseen by Geriatricians e.g. POPS - ‘Proactive care of older persons undergoing surgery’ services. These services assist in identifying modifiable impairments which, if not addressed, would pose increased risk of post-operative problems in older, or less fit, surgical patients(48). Once identified, these impairments may be optimized through prehabilitation.  Carli et al. described mitigation of the post-operative stresses of surgery using an integrated multi-disciplinary approach of prehabilitation in the pre-operative period, highlighting especially the benefits in the older patient (49). Of note, physical activity levels and physical capacity in the general population falls significantly with age. In the UK population, 43% of 55 to 64 year olds are inactive (less than 30 minutes of physical activity per week), rising to 68% inactive in the 75+ years age group. Accordingly, prehabilitation to improve physical capacity is of greater importance in older patients and likely to become increasingly important as activity levels in the general population continues to fall (50)
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5. Provide interventions to promote the physical and psychological health of 
the patient that reduce the incidence and severity of future impairmentsMacmillan Cancer Support (51) encourage the World Health Organisation guideline of Activity in Healthy Adults (52). The recommendation is for “150 minutes/week of moderate intensity or 75 minutes of high intensity activity. Adults (aged 19 – 65+) should also aim to undertake activity to improve muscle strength and balance training sessions twice per week”. The advice for patients with cancer is to aim to achieve the WHO guidelines but to adjust activity according to their physical symptoms and treatment status (51). 
In a study of physical activity guideline compliance in U.S. adults, Tucker et al.(53) reported that fewer than 9.6% met the WHO guideline for physical activity when objectively monitored on accelerometer. In contrast, the self-reported level of compliance was 63%.  In a Sport and Physical Activity: Special Eurobarometer Report (2013), 29% of EU adults claimed to undertake vigorous activity for 1-3 days per week. 25% of adults reported participating in moderate activity, 4-7 days per week (54).
Physical training interventions in past studies described a range of exercises for pre-operative optimization. Some suggested exercise of selected muscle groups to reduce post-op complications e.g. Inspiratory Muscle Training, to selectively attempt to reduce post-operative pneumonia (25-27). The majority of current trials include a combination of aerobic and resistance training programs. (Table1). A meta-analysis by Marzolini et al. reported improved body composition, strength and cardiovascular fitness, and ‘probably quality of life as well’, in combined aerobic and resistance training versus resistance training alone(55). Furthermore, they concluded that in stroke patients, aerobic training may be reduced by up to 40%, but with similar improvements in mobility and VO2peak, if combined with resistance training (56).
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Psychological health of the patient is also important in cancer prehabilitation. The advantageous outcomes of exercise on psychological health during cancer rehabilitation have been reported by Smith et al. (56) and Losito et al. (57,58) These include improved quality of life and cancer-related fatigue. ‘Living with and beyond cancer’ and ‘survivorship’ are terms frequently being used in post-treatment cancer patient groups. Physical exercise before, during and after cancer treatment improves physical status and quality of life (58). 
Prehabilitation, cancer and immunity 
The effect of exercise prehabilitation in cancer may also impact on tumour control through immune system regulation. In a review of patients who undertook monitored exercise following a diagnosis of cancer, there was a lower relative risk of cancer recurrence and cancer-related mortality compared to patients who did little or no exercise. Furthermore, the same patients experienced fewer or less severe treatment side effects (59). Patients who experience complications after surgery have higher rates of cancer recurrence independent of tumour stage (60). This implies an immunological component to cancer recurrence. Terra et al. (61) described inherent activation of  the immune response cascade through exercise, eliciting a pro-inflammatory response during moderate intensity exercise. However, during high intensity exercise an anti-inflammatory response was noted. Hojman (62) further described the effects of exercise on the control of immune cell function, modulation of inflammatory signaling and regulation of systemic inflammation linking these regulatory effects to lowered tumour incidence and disease progression. Pederson et al. linked exercise to reduced tumour growth and through increased infiltration of natural killer (NK) cells in exercised mice (63). The mechanism of increased mobilization of NK cells is speculated to be through increased release of Interleukine-6 (IL-6) myokines in response to muscle contraction.(64) Exercise-induced IL-6 is described as having a pro-inflammatory effect on bacterial infections and contrasting anti-inflammatory inhibiting effect on Tumour Necrosis Factor-alpha (65). Research programs in clinical practice aim to provide evidence that exercise reduces the 
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risk of complications and may also have immunological benefits on tumour control and recurrent disease.
Summary and clinical implications
Mortality rates after oesophagectomy have fallen, however morbidity rates remain high. The introduction of ERAS programs provided a consolidated framework for improvements of care in the peri-operative period and has reduced length of hospital stay. The introduction of prehabilitation programs, in order to optimise patients physically and psychologically for surgery, have proved to be beneficial in some tumour groups. The health benefits, safety and biological benefits on tumour control following exercise have also shown positive results. A number of questions remain in regards to prehabilitation in oesophageal cancer. These include the timing and accessibility of the intervention, how to improve compliance, the optimal makeup of training programmes, how to measure physical performance and, the cost-effective implementation of prehabilitation into standard practice. With a coordinated, multidisciplinary approach to introducing a holistic prehabilitation program in cancer care, there is realistic potential to change the current status quo and improve surgical outcomes, physical health, psychological well-being and long-term survival in these patients. 
Conclusion
‘Living with and beyond cancer’ begins at the time of cancer diagnosis - so too should prehabilitation. Dr Nick Cavill, a health promotion consultant said: “If exercise were a pill, it would be one of the most cost-effective drugs ever invented”. Therefore, the challenge to those making clinical decisions in cancer care is to develop a greater 
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understanding of exercise prehabilitation and its active promotion as an integral part of the treatment pathway. Much is said about empowering patients with long-term conditions and joint clinical decision-making with patients. ERAS provided an excellent matrix for a coordinated, multi-disciplinary approach to peri-operative improvements in patient care. Prehabilitation, or ‘Pre-ERAS’, is the opportunity to broaden the benefits of ERAS to include engagement of the patient in their care from the time of diagnosis.
Conflict of Interest: None
Future research agenda
 To define the timing and accessibility of the exercise prehabilitation 
intervention in order to optimise compliance
 To identify the optimal structure of the exercise program during the 
treatment pathway
 To achieve consensus on how best to measure baseline function and 
monitor physical performance changes during prehabilitation. 
Practice Points
 Exercise during cancer treatment is safe and advisable
 Prehabilitation in cancer should commence at diagnosis
 Benefits of prehabilitation extend beyond physical optimisation and include general health, well-being, psychological improvements and immune function support
 Prehabilitation should form the starting point of Enhanced Recovery After Surgery Programs
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Table 1 Registered Clinical Prehabilitation Trials 
Trial 
Registration Author
Trial Design Study Title Participants Intervention/Exercise Regimen Outcomes
Target/ current 
status 
(intervention: 
control groups)
Adenocarcinoma/Sq
uamous Cell 
Carcinoma
NAC/NACRT
Intervention 
during neo-
adjuvant 
oncological 
treatment and 
surgery 
(continuum of 
care)
Intervention 
before start of 
acute 
oncological 
treatment
Baseline 
measures: 1. 
Physical, 2. 
Psychological
Cardiopulmonary 
exercise testing
Intervention to 
promote 
physical, 
psychological 
health and 
reduce future 
impairments
ClinicalTrials
.gov 
Identifier: 
NCT03418298
 Piraux; Gil les Single group assignment
Prehabilitation in Patients With 
Esophageal or Gastric Cancers
Esophageal and Gastric cancer; Post 
NAC, >2 weeks pre-surgery
Preoperative internet-based program including aerobic and 
resistance training three sessions per week; IMT
Retention; Adherence; Patient 
satisfaction; adverse events 20/recruiting Not specified Not specified Mixed Mixed Mixed
ClinicalTrials
.gov 
Identifier: 
NCT02962219
Lam; Hart
Randomised; Parallel 
assignment
Exercise Prior to Oesophagectomy 
(ExPO)
Oesophageal adenocarcinoma; 3-4 
months before surgery; NAC + 
surgery
1) Behavioural change techniques (BCTs), 2) home inspiratory 
muscle training (IMT), 3) a home exercise programme (HEP) - which 
is also current standard care, 4) a 4 week hospital-supervised 
aerobic and muscle strengthening programme (Hos-PEP) .
Feasibility data on whether PEP is 
acceptable, adhered to and safe, 
and whether it improves patient 
fitness above standard care.
32/recruiting OAC NAC     
ClinicalTrials
.gov 
Identifier: 
NCT02780921
Lacarin; Le Roy
Randomised; Parallel 
assignment
Effect of Prehabilitation in 
Gastroesophageal Adenocarcinoma: 
Study Protocol of a Multicentric, 
Randomised Control Trial
Oesophageal and Gastric cancer; 
pre-chemo (NAC) + surgery
1 hour of supervised exercise for at least 3 days per week, for a 
total of 18 cycles, alternating between aerobic and resistance 
training
% Patients completing oncological 
treatment as determined by MDT 120/recruiting OAC NAC     
ClinicalTrials
.gov 
Identifier: 
NCT02722785
Christensen
Non-randomised; Parallel 
assignment
PeRioperative Study of Exercise 
Training in Patients With Operable 
Cancer of the Gastroesophageal 
Junction (PRESET)
Operable gastro-oesophageal 
junction; pre-surgery but during NAC 
not specified
After a light warm-up, patients will perform 20-30 min of aerobic 
interval training of stationary bicycle. Resistance training 
comprises 4 exercises for the major muscle groups: chest press, leg 
press, lateral pull, and knee extension with 3-4 sets of 8 to 15 
repetitions
Safety and Feasibility of pre-and-
post-op exercise -  Incidence of 
adverse events; Adherence to 
program
40/active, not 
recruiting OAC Not specified  
ClinicalTrials
.gov 
Identifier: 
NCT02680990
Hershey; Cooper
Randomised; Parallel 
assignment
Resilience and Exercise in Advanced 
Cancer Treatment (REACT)
Operable Oesophageal, Gastric and 
Pancreatic Cancer; during NAC
Sessions completed 3 times/week: 3 sets of 6 exercises: 1. chair 
stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 
6. calf raises. In addition, Band Together participants will be asked 
to work up to a walking goal of 10,000 additional steps per week
Feasibility: Adherence and 
Contamination 60/14 - closed OAC NAC/NACRT    
ClinicalTrials
.gov 
Identifier: 
NCT01952210
Xu; Chen
Randomised; Parallel 
assignment
Effectiveness of a Nutritional 
Consultation and Exercise Program in 
Esophageal Cancer Patient: Walk and 
eat
Neo-adjuvant chemoradiotherapy in 
oesophageal cancer (SCC)
Upper extremity muscle training and walking exercise at 45%-65% 
of maximal heart rate reserve, 3 times per week, 20-30 minutes per 
session.
6MWT; hand grip strength; lean 
muscle mass; body weight change; 
Nutritional status
56/50 - 
completed; 
published
OAC/SCC/NET NAC/NACRT   
ClinicalTrials
.gov 
Identifier: 
NCT01666158
Carli
Randomised; Parallel 
assignment
Prehabilitation for Esophageal 
Resection Surgery
Oesophageal cancer surgery; 4 
weeks before elective surgery
20 min of general exercise training, 3 days per week, alternating 
between aerobic and resistance training
Enhance Postoperative Functional 
Capacity Following Esophageal 
Resection; 6MWT
68/68 Not specified Not specified  
ClinicalTrials
.gov 
Identifier: 
NCT02950324
Allen; Sultan
Randomised; Parallel 
assignment
Does Prehabilitation Improve Exercise 
Performance and Insulin Resistance 
After Surgery for Oesophago-gastric 
Cancer?
Oesophago-gastric cancer; 17 weeks 
before surgery Multimodal programme that involves 15 weeks of exercise
Improved performance on CPEX; 
reduced insulin resistance; HRQL 50/recruiting OAC NAC     
ClinicalTrials
.gov 
Identifier: 
NCT03626610
Zylstra; Davies
Non-randomised; Parallel 
assignment
Pre-EMPT: Prehabilitation in 
oEsophageal Malignancies on a 
Perioperative Treatment pathway 
including neo-adjuvant chemotherapy
Operable oesophago-gastric 
adenocarcinoma; during neo-
adjuvant chemotherapy and  pre-
surgery
WHO guidelines for exercise in adults as minimum; 10,000 
steps/day (measured using wearable device); Strength, core and 
relaxation exercise training commencing before NAC
Cardiopulmonary fitness; LOS & 
Post-op complications; 
Commencement of recommended 
adjuvant treatment; HRQL; DFS
66/recruiting OAC NAC     
ClinicalTrials
.gov 
Identifier: 
NCT02478996
Pfirrmann; Gockel 
Randomised; Parallel 
assignment
Internet-based Perioperative Exercise 
Program in Patients With Barrett's 
Carcinoma Scheduled for 
Esophagectomy (iPEP)
Barrett's carcinoma scheduled for 
surgery; 8-12 weeks before and after 
surgery
 Internet-based perioperative exercise program (iPEP), including 
daily endurance, resistance and ventilation training Peak oxygen uptake (VO2peak) 80/recruiting OAC Not specified  
ACTRN126130
00664741
Boden et al. 
(2018)
Randomised; Parallel 
assignment
LIPPSMAck POP trial - Lung Infection 
Prevention Post Surgery (Major 
Abdominal) with Pre-Operative 
Physiotherapy education
Upper abdominal surgery; 2 weeks 
before surgery; NAC not specified
Interview and breathing exercise instructions Pulmonary Complications
377/441; 
completed; 
published
Not specified - mixed 
tumour groups
Not specified
Unknown Dettling et al. 
(2012)
Non-randomised controlled 
trial
Feasibility and Effectiveness of 
Pre-operative Inspiratory Muscle 
Training in Patients Undergoing 
Oesophagectomy: A Pilot Study
Oesophageal cancer; NAC not 
standard care
Lung Function test Post-operative pneumonia 90/48:42 Not specified Not specified 
ClinicalTrials
.gov 
Identifier: 
NCT01893008
Valkenet et al. 
(2018)
Randomised; Parallel 
assignment
PREPARE: Pre-operative Inspiratory 
Muscle Training in patients undergoing 
oesophageal resection
Oesophageal resection - at least 2 
weeks before surgery
Inspiratory Muscle Training using flow-resistance; 1 physiotherapy-
lead training session
Decreased pulmonary 
complications after esophgeal 
resection
245/120:121; 
completed; 
published
Not specified NACRT 
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Enhanced Recovery
Introduction
Since the enhanced recovery after surgery (ERAS) study group published the first guidelines advocating the importance of multidisciplinary team collaboration to advance the recovery of patients after surgery this approach has been embraced across a range of surgical disciplines. A number of centers have established standardized care pathways for management of patients undergoing oesophagectomy (Table 1). In the absence of formal ERAS guidelines for oesophagectomy, these pathways have been drawn from other examples within surgical oncology. Variation in the design and implementation of care pathways within different institutions continues to be a limiting factor when seeking to derive summative evidence for wider implementation. Notwithstanding there have been reports that standardization of care can be associated with improvement in important outcomes in patients undergoing oesophagectomy, including anastomotic leak and length of hospital stay (1). An overview of major studies in ERAS in oesophagectomy patients is presented in Table 2.
The purpose of this review is to discuss the core elements of an enhanced recovery program for oesophagectomy that is applicable to both malignant and benign disease. For convenience this review has been divided between interventions that are most applicable to intra-, and post-operative periods. Although pre-operative identification of potential barriers to successful enhanced recovery is a core component of any successful ERAS program, a commentary on these interventions as part of prehabilitation was provided earlier within this chapter. 
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Table 1. Example of institutional standardized clinical pathway for oesophagectomy from Virginia Mason Medical Center
Initial Contact
Initial  
Assessment / 
Staging
Pre-op 
Arrangement 
/Restaging
Surgery POD 0PPICU “step-down unit”
POD 1
Surgical ward
POD 2-3
Surgical ward
POD 4-5
Surgical ward
POD 6-7
Surgical ward / DC
M
ed
ic
at
io
n • Antiemetic Protocol
• Continue Beta Blocker, and 
ASA
• IV PPI – Monitor gastric pH
• Continue Beta Blocker + ASA
• Selective start routine meds 
down J-tube
• IV PPI (esomeprazole)
• Consider
– Dulcolax sup
– Lasix
• Start oral crushed PPI when 
NGT removed
• Consider Erythromycin if 
delayed gastric emptying
• Continue oral PPI
• Transition all meds to J-tube
• Oral PPI
• All routine meds and analgesics 
given liquid or crushed via J-tube
Pa
in
 
Co
nt
ro
l • PCEA ± PCA
• Avoid bolus adjustment
• Consider
– IV Acetaminophen
• PCEA ± PCA
• Consider Ketorolac
• PCEA ± PCA
• Consider Ketorolac
• Transition from PCEA
• J-tube  scheduled oxycodone
± NSAID
• Provide prescriptions 24-48 hrs 
prior Discharge
Po
si
ti
on
in
g 
&
 
M
ob
ili
za
ti
on • Keep HOB>45°
• Compress Stocking
• Chair 4-6/hr postop
• 100ft walk 12-14/hr 
post-op
• Keep HOB>45°
• Compress Stocking
• 200ft walk x 2 in PPICU
• Transfer to ward
• Keep HOB >45°
• Compress Stocking
• In chair 2-3 hr/day
• 200ft walks 6-8/day
• Keep HOB > 45°
• Compress Stocking
• Chair 80% of day
• Independent Activity
• Keep HOB >45°
• Chair 80% of day
• Independent Activity
• Discharge Planning
H
em
od
yn
am
ic
s 
&
 
Re
sp
ir
at
or
y
• Avoid CPAP
• Maintain MAP>70mmHG
Treat MAP<70mmHg
• Decrease epidural rate/no 
bolus
• Epinephrine Drip
• Infuse up to 2l crystalloid
• Maintain MAP>70mmHG
• Avoid CPAP • Reinitialize CPAP if needed • Routine Vital Signs • Routine Vital signs
Im
ag
in
g
• Recovery room
post-op CXR • CXR (2 view)
• CXR (2 view)
• Witnessed UGI POD 3-4 • CXR (2 view)
• CXR (2 view) for clinical 
issues only
D
ra
in
ag
e 
tu
be
• CD to 20 cm suction
• NGT – low cont. wall 
suction
• Foley Catheter 
• D/C apical CD if no air leak & 
low output
• CD water seal
• May D/C 2nd CD (except Ivor 
Lewis) 
• F/U CXR in 4hr
• Ivor Lewis: CD till oral intake
• D/C NGT when contrast study 
shows good gastric emptying 
(target day 3-4)
• In IL D/C 2.CD when oral 
intake
N
ut
ri
ti
on • IV Fluid basal rate 70cc/hr 
D5/½NS
• MAP<70 consider fluid 
bolus (max 2L)
• IV Basal rate 50cc/hr D5/½NS
• J-tube 10ml/hr and selective 
meds.
• J-tube 30cc/hr advance to 
goal
• No oral intake
• D/C IV fluids
• J-tube target rate & transition 
to nocturnal feed
• Start oral protocol* when no 
gastric emptying delay on 
UGI
• Advance oral protocol
• J-tube teaching for patient and 
family
Phone interview
Within 24 hr of 
referral
– PMH 
– Current Symptoms
– Assess Dysphagia 
and weight loss
– Current 
Investigations
– Travel 
Arrangements
Ensure previous 
notes, investigations, 
films, pathology are 
available
Preparation of 
tailored patient 
schedule
≥ physiologic and 
staging investigations 
completed in 48 hr
Consultations
– Medical Oncology
– Radiation Oncology
– Cardiology
– Thoracic Surgery
– Gastroenterology
Investigations
– CT
– PET/CT
– EGD, EGD-US
– Path review
– PFT
– Selective objective 
cardiac testing
Nutritional 
Assessment
Thoracic Tumour 
Board
Within 7 days of 
consult
Communicate results 
following day to 
patient and referring 
physician.
Initiate Neoadjuvant 
Therapy
Appropriate patients
with cT2-4, N1-4, Mx
Restaging 
2-4 Weeks
Following 
neoadjuvant therapy
– CT
– EGD + US
– Tumour Board
Surgical Approach
Tailored according to
– Tumour / Barrett 
characteristics
– Patient Physiology
– Previous Surgery
– Conduit Availability
Thoracic epidural 
placed 
preoperatively
– Bupivacaine 
0.05%
– Hydromorphone 
10µg/ml
Single dose 2nd 
Generation 
Cephalosporin
Selective SQ 
Heparin 
Minimize blood 
loss / transfusion
No routine central 
venous catheter
Restrictive fluid 
administration 
intra-operatively
Target <4l 
crystalloids
Immediate 
Extubation
On table 
epidurogram 
to verify correct 
epidural placement
Immediate Post-op 
Anesthesia
PCEA with pain 
service monitoring, 
no bolus
Admit to PPICU
(Step-down unit)
Co
ns
ul
t • Pain service
• PSY elderly patients
• Selective RT
• PT mobilization
• Dietary
• Dietary 1-2 days prior to D/C
• Social work – PRN 
• ± Rehab
• Home Health Care Services 
for J-tube
• Dietary 
– Nutritional oral & J-tube 
protocol over next 4-6 weeks
1. 
Description 
Surgery & Pathway
2. 
Description
Surgery & Pathway
3. 
Description
Surgery & Pathway
Critical 
Measurable Goals
Immediate Extubation
Maintain MAP >70 
mmHG
Mobilize Day of Surgery
Transfer to Ward
Initiate Enteric Feeding
Mobilize 2-4 Walks
J-Tube Feeding to Goal
Assess Gastric Emptying
Remove NG & Chest Drain
Independent Mobility
Start Oral Intake Discharge Day 6-7
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* Oral Protocol: Ward nurse direct advancement of liquid oral intake from 15cc/hr ≥ ⅔ Cup/hr PMH past medical history, CT computed tomography, PET/CT positron emission tomography w CT, EGD gastroscopy, US ultrasound,  PFT pulmonary function test, PPICU post procedural intensive care unit, PCEA percutaneous epidural analgesia, PCA patient controlled analgesia, POD post-operative day, HOB head of the bed, MAP middle arterial pressure, CXR chest x ray, CD chest drain, NGT nasogastric tube, PSY psychiatric consult, RT respiratory therapy, PT physical therapy, IV intravenous, PPI proton pump inhibitor, J-tube jejunostomy, NSAID non steroid anti-inflammatory drug, D/C discharge, F/U follow up
Routine post discharge goals
• Represent at MTB (recommendations to referring and primary 
care MD’s)
• J-tube removed 4-12 weeks post discharge
• Q.O.L and patient satisfaction assessment
• Commit to 3 years follow-up
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Table 1. ERAS studies in oesophagectomy 
Author Year Country Design Patient No. 
(total/ERAS)
Outcome Ref
Benton 2018 Australia Retrospective 33/17 ERAS was associated with no difference in hospital stay (2)
Blom 2013 Netherlands Prospective 181/103 ERAS was associated with reduced hospital stay but equivalent postoperative morbidity (3)
Cao 2013 China Retrospective 112/55 ERAS was associated with reduced hospital stay and postoperative morbidity (4)
Chen 2016 China Prospective 260/128 ERAS was associated with reduced hospital stay but equivalent postoperative morbidity (5)
Findlay 2015 UK Retrospective 132/55 ERAS was associated with no difference in hospital stay and postoperative morbidity (6)
Ford 2014 UK Prospective 116/75 ERAS was associated with reduced hospital stay but equivalent postoperative morbidity (7)
Giacopuzzi 2017 Italy Prospective/retrospective 29/22 ERAS was associated with no difference in hospital stay and postoperative morbidity (8)
Li 2012 Canada Prospective 106/59 ERAS was associated with reduced hospital stay and postoperative morbidity (9)
Li 2017 China Prospective 110/55 ERAS was associated with reduced hospital stay and postoperative morbidity (10)
Markar 2014 USA Prospective 275/183 ERAS was associated with reduced hospital stay but equivalent postoperative morbidity (11)
Munitiz 2015 Spain Retrospective 148/74 ERAS was associated with reduced hospital stay but equivalent postoperative morbidity (12)
Preston 2013 UK Prospective 24./12 ERAS was associated with reduced hospital stay and postoperative morbidity (13)
Shewale 2015 USA Retrospective 708/386 ERAS was associated with reduced hospital stay and postoperative morbidity (14)
Tang 2013 UK Prospective/retrospective 63/36 ERAS was associated with reduced hospital stay but equivalent postoperative morbidity (15)
Tomaszek 2010 USA Retrospective 386/110 ERAS was associated with reduced hospital stay but equivalent postoperative morbidity* (16)
Zehr 1998 USA Prospective/retrospective 152/96 ERAS was associated with reduced hospital stay (17)
Zhao 2014 China Prospective 68/34 ERAS was associated with reduced hospital stay but equivalent postoperative morbidity (18)
*Lower rates of anastomotic leak observed
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Multidisciplinary engagement
The multidisciplinary engagement, often in the form of a formal tumour board, has become an established part of the management of patients with oesophageal cancer. In addition to oncological consideration, other important determinants of patients care including: comorbidities, physiological reserve and nutrition often feature as a component of tumour board discussions. The tumour board should actively seek engagement from the full spectrum of the multidisciplinary team including the patient, who should remain the central focus and be kept informed of recommendations. The needs of patient populations, who do not traditionally receive the benefit of formal multidisciplinary discussion, such as those with benign or emergency indications of for oesophagectomy, should not be forgotten.
Operative components
Timing of surgeryFor patients receiving neoadjuvant chemoradiotherapy the competing pressures of allowing adequate time to recover from therapeutic toxicities in the presence of ongoing tumour regressive effects versus the risk of new tumour progression and evolving fibrosis of surgical tissue planes must be carefully balanced. Current recommendations are for an interval of 6-10 weeks after neoadjuvant chemoradiotherapy and 6-8 weeks after neoadjuvant chemotherapy before oesophagectomy (19-21).
Surgical technique
Surgical approach: Recently published data from a collaboration of 24 high volume centers in 14 countries indicate that approximately half (48%) of all oesophagectomies are currently performed by a minimally invasive approach. This trend is reflective of a desire to reduce the magnitude of surgical trauma that is associated with this operation. Questions however remain as to the safety and efficacy of both open and minimally invasive techniques. There have been eleven meta-analyses comparing the outcomes of open versus minimally invasive oesophagectomy (22-32). Taken together their findings suggest the minimally 
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invasive techniques are associated with lower overall postoperative morbidity, early mortality and length of hospital stay. Minimally invasive procedures were more often associated with longer operative time but equivalent lymph node harvest (26, 29, 30). Overall survival was either equivalent (23, 24) or superior (26) in the minimally invasive cohort. 
Lymphadenectomy: The extent of the lymphadenectomy performed during oesophagectomy for oesophageal cancer remains a contentious subject. Proponents of radical lymphadenectomy cite evidence that it reduces local recurrences rates and improves long-term survival as well as supporting more accurate pathological staging (33-36). In comparison those in favor of a more conservative approach would contend that such an approach increases perioperative morbidity with inconclusive evidence supporting improved survival. Current recommendations are that the extent of lymphadenectomy should reflect the location of the tumour within the esophagus in addition to its histological stage (33-35, 37). 
Oesophageal reconstruction: Several factors should be considered when selecting the most appropriate method of oesophageal reconstruction: the type of conduit, the route of the conduit to the site of anastomosis and the method of anastomosis. In the majority of cases a conduit formed from the tubularized stomach is favored, both because of the accessibility of the gastric remnant and the requirement for a single anastomosis. Alternative conduits such as the colon and jejunum, may be used in certain circumstances, including: significant invasion of the proximal stomach by tumour and in cases where there has been a history of prior gastric resection or compromise of a previous gastric conduit.
Anastomosis: Evidence supporting an optimal method of anastomosis formation is lacking. Meta-analysis of studies that compared anastomotic technique in oesophagectomy found that linearly stapled hybrid anastomoses (38) was associated with a reduced leak rate compared to hand-sewn anastomosis (39). The same was not however true for circular stapled techniques whose leak rates were comparable to hand sewn anastomosis (39). In the absence of strong 
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evidence for or against a particular form of anastomosis, surgeons are recommended to develop confidence in one or a number of techniques that may be adapted to difference clinical scenarios should a need present itself.
Surgical drainsThe long held convention of placing surgical drains at the time of oesophagectomy is a practice that occurs largely in the absence of evidence-based guidelines. Whilst chest drains are often favored for their ability to drain air and fluid from the thoracic cavity potentially heralding clinically significant anastomotic or chylous leak, they may be associated with pain and reduced mobility (40). Whilst many surgeons may exercise caution when removing chest drains after oesophagectomy, opting to wait for daily draining levels to fall below 100-150ml, higher output volumes have been proposed as safe by other studies albeit after pulmonary resections (41-43). Likewise in pulmonary surgery use of a single, centrally placed, drain is considered as effective as two drains with the added effect of having less associated pain (44, 45). The use of active drainage was also not found to confer and added benefit in patients after oesophagectomy (46). There is currently insignificant evidence to support the use of either cervical or thoracic peri-anastomotic drains. 
Nasogastric tube placementSince the widespread adoption of ERAS program within gastrointestinal surgery the routine used of nasogastric tubes for postoperative gastric decompression has been virtually eradicated from clinical practice. In the case of oesophagectomy justification of their use has often centered on the requirement for conduit decompression that may in turn prevent aspiration pneumonia and anastomotic leak. A recently published meta-analysis found that peroperative or early (day 2) nasogastric tube removal did not result in increased morbidity or mortality (47). Furthermore early removal was associated with shorter hospital stay. Current recommendations are for nasogastric tube decompression following oesophagectomy with early removal considered on postoperative day two in the absence of any contraindications.
ACCEPTED MANUSCRIPT
31
Anesthetic managementIntraoperative actions and events have the potential to significantly impact on postoperative outcomes. The aims should be to minimize local (pulmonary) and systemic inflammatory responses associated with oesophagectomy and to facilitate early extubation.
Interventions that may facilitate early extubation after oesophagectomy include use of bispectral index to monitor the depth of anesthesia (48) and use of short or intermediate acting neuromuscular blockers at appropriate doses (49). 
Frequent requirement for periods of single lung ventilation during oesophagectomy serves as an additional challenge when defining anesthetic and ventilator strategy. Whilst there is limited evidence from studies in patients undergoing oesophagectomy the adoption of lung protective ventilator strategies during both double and single lung ventilation has been advocated. Lung protective ventilation is acknowledged to reduce both the local and systemic inflammatory response facilitating early extubation with a lower risk of re-intubation. There is emerging evidence that driving pressures is the principal mediator of lung injury during ventilation (50). Accordingly minimization of driving pressure as well as limiting the duration of one lung ventilation should be clear objectives in preventing lung injury during oesophagectomy.
Higher rates of respiratory complications and delayed extubation are recognized sequelae of increased intravenous fluid administration during oesophagectomy (51-53). Conversely overly restrictive fluid usage may be responsible for end organ damage through hypoperfusion (54). Current guidance support balanced fluid therapy with zero weight gain. Current recommendations are for the use of balanced crystalloids solution as opposed to 0.9% saline and colloids (55, 56).
Hypotension in the presence of normovolaemia is a common occurrence after oesophagectomy and is often a consequence of the vasodilatory effects of epidural analgesia. In such circumstances vasopressors may be required to maintain of mean artery pressure at a target of 70 mmHg and urine output >0.5ml/Kg/hr 
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without further provision of intravenous fluids. Lower urine output in patients without risk factors for acute kidney injury may also be tolerated (57).
Post oesophagectomy nutritionRisk of aspiration pneumonia and anastomotic disruption are often cited as the main reasons for a delay in the initiation of oral intake after oesophagectomy. Whilst parenteral nutrition has been described in this setting, current evidence favors feeding via an enteral route wherever possible (58, 59). Utilization of the intestinal tract over parental routes has the added advantage of suppressing the surgical stress response as well as helping to maintain gastrointestinal health through preservation of its immune and barrier functions.
The preferential route for establishing early enteral feeding after oesophagectomy is via a feeding jejunostomy placed at the time of surgery. Complications of jejunal feeding tubes are acknowledged but are most often minor events such as tube dislocation, occlusion, leakage, entry site infection and gastrointestinal disturbance (60). Major tube related complications including death (0-0.5%) and reoperation (0-2.9%) are reported in a small number of patients (60). Feeding via either a nasojejunal or nasoduodenal tube offers an alternative and potentially safer route for enteral feeding, however patient acceptability and high rates of dislocation limit their use (60). Several studies have examined the feasibility and safety of early oral feeding after oesophagectomy in an effort to subvert the widely held dogma against this practice. When compared to patient whose oral intake was delayed until postoperative day five following oesophagectomy, early oral feeding on postoperative day one was not associated with higher rates of complications (60, 61) and intensive care and hospital stay were significantly shorter (62). 
Once a route of providing enteral nutrition has been established full caloric requirements should be targeted by postoperative day 3-6 (60). There is no clear evidence supporting the use of pharmaconutrition, over traditional enteral feeding solutions, as such their use is not currently supported (63). 
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Postoperative components
Care levelOwing to the magnitude of the operation and historical practice of prolonged elective intubation after oesophagectomy, it has historically been a requirement that patients were cared for within an intensive care unit during the immediate postoperative period. In the absence of a specific clinical indication the practice of prolonged mechanical ventilation and sedation after oesophagectomy should be avoided. This practice results in continued exposure of the lungs to an injurious stimulus, hemodynamic instability that can precipitate fluid overload and a delay in the ability to initiate physical rehabilitation through early mobilization. 
In the majority of cases patients can be extubated immediately after oesophagectomy, thereafter they should be transferred to a clinical environment that is able to provide the required level of physiological and physical support at each stage of recovery. Initially this may involve the intensive care unit, but in some hospitals may include other facilities such as high dependency, step down or progressive care units. Prior to hospital discharge patients would be expected to transfer to a general surgical ward. 
Pain controlAdequate control of postoperative pain is vitally important in facilitating patients’ ability to comply with fundamental aspects of an ERAS program, including early mobilization and respiratory exercises. Inadequate pain control is associated with pulmonary complications, venous thrombosis and prolongation of the surgical stress response (64). The physiological and psychological implications of inadequate pain control may contribute to higher opioid usage and associated side effects. Choice of analgesia should reflect a multimodal approach that encompasses local and regional anesthetic techniques and seeks to minimize the opioid usage.
For open surgery thoracic epidural analgesia may offer the optimal method of ensuring analgesia. Concern for motor and sympathetic blockade that can result 
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in unwanted side effects of epidural analgesia may be mitigated through use of dilute local anesthetic and opioid infusions and avoidance of bolusing. By ensuring normovolemia and the cautious use of vasopressors in selected patients, the risks of hypotension can be further reduced.
Use of paravertebral block that can be placed under direct vision has emerged as an alternative to thoracic epidural, with several publications demonstrating equivalent analgesia without the unwanted side effects (65-67). Use of paravertebral blocks may be particularly useful where the abdominal component of oesophagectomy has been competed laparoscopically.
Additional analgesic agents that should form part of the multimodal management of oesophagectomy patients include: acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), gabapentinoids and ketamine. The use and titration of these and other agents should ideally be overseen by a specialized anesthesia pain service.
Mobilization Early postoperative mobilization is a central tenet of almost all ERAS programs as it serves to prevent the well-documented detrimental effects of bed rest. In the absence of any contraindication it is reasonable to target patient mobilization on the day of surgery. Following this mobilization should continue with a daily incremental increase in expected activity. Independent mobilization is typically a targeted pathway goal prior to discharge.
Pharmacological prophylaxisConsideration for the use of one of a number of pharmacological agents to prevent adverse outcomes after oesophagectomy should be considered in all patients. For the most part evidence for the use of pharmacological prophylaxis in patients who have undergone oesophagectomy is extrapolated from studies in general surgical populations. A summary of recommended prophylactic drugs and indications for their use is presented in Table 3.
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In addition to these prophylactic drugs special consideration should be given to the use of pharmacological agents for glycemic control and treatment of common complications including arrhythmias and infections. Whilst there is limited evidence regarding the optimal approach to managing these complications, including the choice of pharmacological agents, individual centers should take steps to develop algorithms for their early detection and treatment. Engagement of the wider multidisciplinary teams including specialists in internal medicine, infectious disease and microbiology is recommended.
Table 3. Pharmacological prophylaxis in patients undergoing oesophagectomy  
Class Intention Indications Thromboprophylaxis All patients in the absence of a specific contraindication should receive LMWH or equivalentCardiovascular Beta-blockade Beta blockade should be considered in patients who are long-term used of beta-and high risk beta-blocker naive patients with coronary artery disease 
Antiemetics Prevention of PONV Patients identifiable risk factors should be considered for combination therapy including two or more antiemetic agents one of which should be a 5-HT3 antagonist (e.g. ondansetron)
Antibiotics Prevention of surgical site infection All patients should receive a short course (<24hrs) of intravenous antibiotics with initial dose given prior to surgical incision
Bowel 
stimulation
Prevention of postoperative ileus Use of simple intestinal including oral laxatives, glycerine suppositories and chewing gum should be considered in all patients LMWH, low molecular weight heparin. 5-HT3, 5-hydroxytryptamine receptor
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Audit
To ultimately be successful in improving patient care, individual centers must develop a detailed understanding of their own practice and how this impacts upon outcomes. The introduction of any change in care should be preceded by an assessment of practice in the form of a clinical audit. Once completed this audit will serve as a benchmark against which all subsequent iterations of care can me measured. In addition to assessing outcomes such audits serve as a valuable method of evaluating compliance with guidelines. The ERAS society, amongst others, has demonstrated that regular audit can improve guideline compliance and a persistent reduction in perioperative morbidity, length of stay and economic cost of care (68-71). There is emerging evidence that compliance with ERAS guidelines is associated with improved long-term survival after cancer surgery (72). It follows that failure to commit to a process of regular audit can result in a decline in adherence to guidelines and outcomes (73). 
Future Perspective: the role of ERAS in maintaining oesophagectomies 
position in the treatment of oesophageal cancer
Oesophagectomy has historically been identified as the ‘Gold Standard’ treatment for oesophageal cancer. This is in spite of the realization that the operation has higher levels of Morbidity and Mortality than virtually any other oncologic operation. A recent comprehensive review of the short term contemporary outcomes of oesophageal resection have demonstrated that even in High volume centers; 59% of patients will have complications and 90 day mortality remains 4.5% (74).
Definitive and Neoadjuvant Chemoradiotherapy has demonstrated the ability to eliminate regional disease in a significant component of patients with adenocarcinoma and squamous cell cancer. Many centers are citing current levels of morbidity and mortality associated with the surgical treatment of oesophageal cancer to question its ‘Gold Standard’ designation. In addition, current 
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randomized studies in Europe specifically the SANO and ESOSTRATE trials are reviewing the potential to apply a ‘surgery as needed’ approach to patients with clinical complete responses.Surgeons must look to improve outcomes associated with oesophagectomy to a point where mortality is rare and complications occur less frequently. The best infrastructure for this to occur is for oesophageal resections to be centralized to high volume centers. These centers should all initiate a standardized ERAS program and monitor its successful application and acceptance by the multidisciplinary team.
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Clinical practice points:
 Oesophagectomy is a complex surgical procedure associated with high rates of morbidity and mortality
 Adoption of standardized ERAS guidelines in oesophageal surgery, but have the potential to improve clinical outcomes
 Such guidelines should reflect standard issues related to enhanced recovery as well as those unique to oesophageal resection
 The importance of a multidisciplinary team approach should be emphasized 
 Regular audit of practice and outcomes is recommended
Research agenda:
 Further high quality clinical studies are however needed to clarify the specific role of ERAS guidelines within oesophagectomy and oesophageal surgery
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